-
Syros Pharmaceuticals (SYRS) Reports Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene
-
Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 52c, provides cash guidance
-
Piper Sandler Reiterates Overweight Rating on Syros Pharmaceuticals (SYRS)
-
TD Cowen Reiterates Buy Rating on Syros Pharmaceuticals (SYRS)
-
Syros Pharmaceuticals (SYRS) PT Lowered to $5 at Piper Sandler
-
Syros Pharmaceuticals (SYRS) PT Lowered to $6 at H.C. Wainwright
-
Syros Pharmaceuticals (SYRS) Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
-
Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 18c
-
TD Cowen Reiterates Buy Rating on Syros Pharmaceuticals (SYRS)
-
Piper Sandler Reiterates Overweight Rating on Syros Pharmaceuticals (SYRS)
-
H.C. Wainwright Reiterates Buy Rating on Syros Pharmaceuticals (SYRS)
-
Brookline Capital Markets Reiterates Buy Rating on Syros Pharmaceuticals (SYRS)
-
JMP Securities Reiterates Market Outperform Rating on Syros Pharmaceuticals (SYRS)
-
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions

